BIIB
ChallengerBiogen
$176.37
+1.98%
as of 13 Apr
Power Core
Biogen's moat is its deep institutional expertise in neuroscience drug development, spanning biology, clinical trial design, and regulatory navigation in CNS disorders, a domain where most competitors fail.
Direction of Movement
Lateral Transition With Upward Optionality If Execution Delivers
ROC 200
+35.3%
BIIB
Biogen
$176.37
+1.98%
as of 13 Apr
DCF Fair Value: $751.23
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
Biogen Inc. is a multinational biotechnology company focused on the discovery, development, and delivery of therapies for neurological, autoimmune, and rare diseases. Its marketed portfolio features multiple sclerosis treatments including Avonex, Tysabri, Tecfidera, Vumerity, and Fampyra, alongside Spinraza for spinal muscular atrophy and other products addressing neurodegenerative and neuromuscular conditions. Biogen Inc. advances an active research and development pipeline targeting Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and additional central nervous system disorders, employing innovative modalities such as antisense oligonucleotides and monoclonal antibodies. The company collaborates with academic institutions and biotechnology firms worldwide to progress late-stage clinical candidates. Operating through global research facilities, manufacturing sites, and commercial offices, Biogen Inc. serves patients and healthcare providers in more than 90 countries across North America, Europe, Japan, and emerging regions. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen Inc. plays a pivotal role in neuroscience research and biopharmaceutical innovation for serious medical conditions.